Literature DB >> 19191184

Effect of intravenous albumin on endotoxin removal, cytokines, and nitric oxide production in patients with cirrhosis and spontaneous bacterial peritonitis.

Tai-An Chen1, Yu-Chen Tsao, Angela Chen, Gin-Ho Lo, Chiun-Ku Lin, Hsien-Chung Yu, Lung-Chih Cheng, Ping-I Hsu, Wei-Lun Tsai.   

Abstract

OBJECTIVE: In patients with cirrhosis and spontaneous bacterial peritonitis (SBP), the use of intravenous albumin has been shown to prevent deterioration of renal function and to decrease the mortality rate, but the mechanisms remain unclear. The purpose of this study was to characterize the mechanisms of action of albumin with the focus on endotoxin and cytokines.
MATERIAL AND METHODS: Thirty patients with SBP were divided into two groups. Group 1 received antibiotics and albumin infusion (20% 50 cc every day for 3 days) and Group 2 received antibiotic treatment only. Twenty-four cirrhotic patients with sterile ascites were enrolled in Group 3 and received albumin infusion (20% 50 cc every day for 3 days). Plasma and ascitic fluid concentrations of endotoxin, nitric oxide products (NOx), tumor necrosis factor (TNF)-alpha, and interleukin (IL)-6 were analyzed before and after treatments, respectively.
RESULTS: Combination therapy of albumin and antibiotics can significantly (p<0.01) reduce plasma levels of TNF-alpha and IL-6, and ascitic fluid levels of endotoxin, TNF-alpha and IL-6 in cirrhotic patients with SBP. Without the addition of albumin to an antibiotic regimen, the plasma and ascitic fluid levels of NOx increased significantly in patients with SBP (p=0.005 and p=0.004, respectively).
CONCLUSIONS: The results confirm that the beneficial effects of albumin are related to the reduction of the levels of TNF-alpha and NOx in both plasma and ascitic fluid. The infusion of albumin continuously for 3 days in addition to antibiotic treatment at the time of SBP detection is recommended as an effective therapy for patients with cirrhosis and SBP.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19191184     DOI: 10.1080/00365520902719273

Source DB:  PubMed          Journal:  Scand J Gastroenterol        ISSN: 0036-5521            Impact factor:   2.423


  30 in total

1.  Concerning Chapter 5 - Human Albumin; in Cross-Sectional Guidelines for Therapy with Blood Components and Plasma Derivatives, 4th ed. Transfus Med Hemother 2009;36(6):399-407.

Authors:  Albert Farrugia
Journal:  Transfus Med Hemother       Date:  2010-03-15       Impact factor: 3.747

Review 2.  Clinical use of albumin.

Authors:  Paolo Caraceni; Manuel Tufoni; Maria Elena Bonavita
Journal:  Blood Transfus       Date:  2013-09       Impact factor: 3.443

3.  The Roche Immunoturbidimetric Albumin Method on Cobas c 501 Gives Higher Values Than the Abbott and Roche BCP Methods When Analyzing Patient Plasma Samples.

Authors:  Johanna Helmersson-Karlqvist; Mats Flodin; Aleksandra Mandic Havelka; Xiao Yan Xu; Anders Larsson
Journal:  J Clin Lab Anal       Date:  2016-05-12       Impact factor: 2.352

4.  Serum albumin level accurately reflects antioxidant potentials in idiopathic nephrotic syndrome.

Authors:  Kazunari Kaneko; Takahisa Kimata; Shoji Tsuji; Tomohiko Shimo; Masaya Takahashi; Sachiyo Tanaka
Journal:  Clin Exp Nephrol       Date:  2011-12-28       Impact factor: 2.801

Review 5.  Albumin in chronic liver disease: structure, functions and therapeutic implications.

Authors:  Rosaria Spinella; Rohit Sawhney; Rajiv Jalan
Journal:  Hepatol Int       Date:  2015-09-29       Impact factor: 6.047

Review 6.  Reappraising the spectrum of AKI and hepatorenal syndrome in patients with cirrhosis.

Authors:  Juan Carlos Q Velez; George Therapondos; Luis A Juncos
Journal:  Nat Rev Nephrol       Date:  2019-11-13       Impact factor: 28.314

7.  Heparin-immobilized microspheres for the capture of cytokines.

Authors:  Jia Duo; Julie A Stenken
Journal:  Anal Bioanal Chem       Date:  2010-09-09       Impact factor: 4.142

8.  Albumin therapy for hepatic encephalopathy: current evidence and controversies.

Authors:  Yu Jun Wong; Jing Hong Loo
Journal:  Metab Brain Dis       Date:  2022-05-26       Impact factor: 3.584

Review 9.  Renal Failure in Patients with Liver Cirrhosis: Novel Classifications, Biomarkers, Treatment.

Authors:  Beate Appenrodt; Frank Lammert
Journal:  Visc Med       Date:  2018-08-14

10.  Hyperoncotic colloids and acute kidney injury: a meta-analysis of randomized trials.

Authors:  Christian J Wiedermann; Stefan Dunzendorfer; Luigi U Gaioni; Francesco Zaraca; Michael Joannidis
Journal:  Crit Care       Date:  2010-10-28       Impact factor: 9.097

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.